Iniciar sesión Regístrese gratis

Last updated: 24 June 2024 at 9:42pm EST

Katherine Rielly-Gauvin Net Worth



Katherine Rielly-Gauvin biography

Katherine Rielly-Gauvin serves as Independent Director of the Company. She has served as the Vice President of Global Commercial Development of AbbVie Inc. (NYSE: ABBV) (“AbbVie”), a pharmaceutical research and development company, since January 2013. At AbbVie, Ms. Rielly-Gauvin is responsible for developing the strategic commercial direction of key compounds in AbbVie’s pipeline across core therapeutic areas in Immunology, Oncology, Neuroscience and Specialty. Prior to joining AbbVie, Ms. Rielly-Gauvin worked in the Johnson & Johnson family of companies across a variety of roles in commercial, medical affairs and research capacities, including Vice President and General Manager for the Janssen Commercial CNS organization. Ms. Rielly-Gauvin holds a Bachelor of Science degree in Chemistry from Simmons College and an MBA in Economics from Rutgers University. Ms. Rielly-Gauvin has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K and was not appointed pursuant to any arrangement or understanding between Ms. Rielly-Gauvin and any other person.

What is the salary of Katherine Gauvin?

As the Independent Director of Liquidia Corp, the total compensation of Katherine Gauvin at Liquidia Corp is $61,100. There are 10 executives at Liquidia Corp getting paid more, with Neal Fowler having the highest compensation of $1,729,090.



How old is Katherine Gauvin?

Katherine Gauvin is 57, she's been the Independent Director of Liquidia Corp since 2019. There are 9 older and 11 younger executives at Liquidia Corp. The oldest executive at Liquidia Corp is Ralph Snyderman, 80, who is the Independent Director.

What's Katherine Gauvin's mailing address?

Katherine's mailing address filed with the SEC is 419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC, 27560.

Insiders trading at Liquidia Corp

Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell y Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.



What does Liquidia Corp do?

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.



What does Liquidia Corp's logo look like?

Liquidia Corp logo

Liquidia Corp executives and stock owners

Liquidia Corp executives and other stock owners filed with the SEC include: